Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
NCT04865159 · Kura Oncology, Inc. · PHASE1 · terminated · last registry update 2023-09-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to recruitment challenges” | – | Registry record, Kura Oncology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FNTA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-31Results posted on the registry: Kura Oncology, Inc., Tipifarnib (NCT02779777)
- 2024-07-31Also stopped (terminated): Kura Oncology, Inc., Tipifarnib (NCT02779777)
- 2024-07-17Results posted on the registry: Kura Oncology, Inc., Tipifarnib (NCT02807272)
- 2024-07-11Results posted on the registry: Kura Oncology, Inc., Tipifarnib (NCT02383927)
- 2024-06-26Results posted on the registry: Kura Oncology, Inc., Tipifarnib (NCT02464228)
- 2024-06-21Results posted on the registry: Kura Oncology, Inc., Tipifarnib (NCT03719690)
- 2024-05-23Also stopped (withdrawn): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Peginterferon Lambda (NCT05953545)
- 2024-03-29Results posted on the registry: Spanish Lung Cancer Group, Tipifarnib (NCT03496766)
- 2023-06-22Results posted on the registry: EIT Pharma, Inc., lonafarnib + Ritonavir (NCT02527707)
- 2023-03-06Also stopped (withdrawn): Kura Oncology, Inc., Tipifarnib + Osimertinib (NCT05693090)
- 2023-02-21Results posted on the registry: EIT Pharma, Inc., lonafarnib + ritonavir (NCT02430194)
- 2022-11-29Results posted on the registry: EIT Pharma, Inc., lonafarnib + peginterferon alfa-2a (NCT02430181)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision